Thursday, May 24, 2012

MediciNova (Nasdaq: MNOV) asthma drug fails trial; shares crash

MediciNova (Nasdaq: MNOV) asthma drug fails trial; shares crashShawshank, VA 5/24/12 (StreetBeat) -- Biopharmaceutical company MediciNova Inc (Nasdaq: MNOV) said its experimental asthma drug failed to meet the main goal of a second mid-stage trial, sending its shares down as much as 51 percent in extended trade.

MediciNova, which is testing MN-221 as a treatment for acute asthma attacks not responsive to standard therapy, said the drug failed to show a statistically significant improvement over a placebo.

MN-221 looks to treat the condition by bypassing constricted airways to deliver the drug directly into the lungs. It aims to improve FEV1 ratio when compared with a placebo.

FEV1 ratio measures volume of air exhaled in the first second.

The trial, however, demonstrated a reduction in hospital admissions when MN-221 was added to standard treatments, the company said in a statement.

MediciNova, which said there were three serious adverse events in the trial, plans to continue development of the drug.

Shares in the San Diego, California-based company fell 51 percent to $1.35 in extended trade. They closed at $2.75 on Wednesday on the Nasdaq.

Please contact for interest in our latest investor relations platform the “CEO Interview Series” with its host Steve Kanaval. The package includes a one-on-one interview with a seasoned industry professional; published segment to our web site with embedded audio/video file; and a compressed file that can be easily e-mailed out to your current and/or potential investors. Please e-mail or call (662) 392-0740 for pricing and scheduling.

StreetBeat Disclaimer

Distributed by Viestly

No comments:

Post a Comment